Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ALLONASDAQ:AMLXNASDAQ:BNTCNASDAQ:CRDL On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeALLOAllogene Therapeutics$1.14+5.6%$1.37$0.86▼$3.78$249.35M0.63.32 million shs2.20 million shsAMLXAmylyx Pharmaceuticals$4.79+1.5%$4.38$1.58▼$7.27$426.99M-0.61.21 million shs498,233 shsBNTCBenitec Biopharma$16.14+12.7%$13.44$5.74▼$16.90$413.18M0.3441,337 shs69,145 shsCRDLCardiol Therapeutics$1.28+10.3%$1.04$0.77▼$3.12$105.74M0.98361,690 shs446,190 shs12 Stocks Corporate Insiders are AbandoningIf a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know? MarketBeat just compiled its list of the twelve stocks that corporate insiders are abandoning. Complete the form below to see which companies made the list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceALLOAllogene Therapeutics+5.56%+2.70%-27.39%-41.54%-53.09%AMLXAmylyx Pharmaceuticals+1.48%-11.79%-4.39%+51.58%+180.12%BNTCBenitec Biopharma+12.71%+18.16%+18.33%+41.45%+88.77%CRDLCardiol Therapeutics+10.34%+20.75%+18.52%+8.47%-45.42%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationALLOAllogene Therapeutics3.7314 of 5 stars4.53.00.00.02.73.30.6AMLXAmylyx Pharmaceuticals3.248 of 5 stars3.61.00.00.03.24.21.3BNTCBenitec Biopharma2.6109 of 5 stars3.62.00.00.03.92.50.0CRDLCardiol Therapeutics2.4123 of 5 stars3.74.00.00.02.20.00.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceALLOAllogene Therapeutics 2.90Moderate Buy$8.44640.74% UpsideAMLXAmylyx Pharmaceuticals 3.13Buy$9.83105.29% UpsideBNTCBenitec Biopharma 3.22Buy$24.7153.12% UpsideCRDLCardiol Therapeutics 3.40Buy$8.67577.08% UpsideCurrent Analyst Ratings BreakdownLatest CRDL, ALLO, AMLX, and BNTC Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/19/2025BNTCBenitec BiopharmaHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$28.00 ➝ $28.005/15/2025ALLOAllogene TherapeuticsCitigroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$8.00 ➝ $4.005/15/2025BNTCBenitec BiopharmaJMP SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingMarket Outperform ➝ Market Outperform$20.00 ➝ $20.005/14/2025ALLOAllogene TherapeuticsPiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$9.00 ➝ $7.005/14/2025ALLOAllogene TherapeuticsTruist FinancialSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$14.00 ➝ $10.005/14/2025ALLOAllogene TherapeuticsRoyal Bank of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Outperform$10.00 ➝ $10.005/14/2025ALLOAllogene TherapeuticsOppenheimerSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOutperform ➝ Outperform$10.00 ➝ $9.005/14/2025ALLOAllogene TherapeuticsRobert W. BairdSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOutperform ➝ Outperform$12.00 ➝ $9.005/14/2025ALLOAllogene TherapeuticsCitizens JmpSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeOutperform ➝ Market Perform5/14/2025AMLXAmylyx PharmaceuticalsMizuhoSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOutperform ➝ Outperform$7.00 ➝ $8.005/9/2025AMLXAmylyx PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$12.00 ➝ $16.00(Data available from 5/29/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookALLOAllogene Therapeutics$22K11,334.24N/AN/A$3.04 per share0.38AMLXAmylyx Pharmaceuticals-$1.27M-335.68$0.87 per share5.51$6.42 per share0.75BNTCBenitec Biopharma$80K5,164.80N/AN/A$3.24 per share4.98CRDLCardiol TherapeuticsN/AN/AN/AN/A$0.32 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateALLOAllogene Therapeutics-$327.27M-$1.23N/AN/AN/AN/A-52.13%-41.29%8/6/2025 (Estimated)AMLXAmylyx Pharmaceuticals$49.27M-$3.11N/AN/AN/AN/A-36.97%-29.61%8/14/2025 (Estimated)BNTCBenitec Biopharma-$21.75M-$1.51N/AN/AN/AN/A-44.61%-41.25%N/ACRDLCardiol Therapeutics-$20.84M-$0.34N/AN/AN/AN/A-194.40%-129.07%7/14/2025 (Estimated)Latest CRDL, ALLO, AMLX, and BNTC EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/14/2025Q3 2025BNTCBenitec Biopharma-$0.36-$0.24+$0.12-$0.24N/AN/A5/13/2025Q1 2025ALLOAllogene Therapeutics-$0.28-$0.28N/A-$0.28$0.00 millionN/A5/8/2025Q1 2025AMLXAmylyx Pharmaceuticals-$0.45-$0.42+$0.03-$0.42N/AN/A3/31/2025Q4 2024CRDLCardiol Therapeutics-$0.08-$0.07+$0.01-$0.07N/AN/A3/13/2025Q4 2024ALLOAllogene Therapeutics-$0.34-$0.28+$0.06-$0.28$0.01 millionN/A3/4/2025Q4 2024AMLXAmylyx Pharmaceuticals-$0.49-$0.55-$0.06-$0.55N/A($0.67) millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthALLOAllogene TherapeuticsN/AN/AN/AN/AN/AAMLXAmylyx Pharmaceuticals$1.0221.21%N/AN/A N/ABNTCBenitec BiopharmaN/AN/AN/AN/AN/ACRDLCardiol TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioALLOAllogene TherapeuticsN/A9.359.35AMLXAmylyx PharmaceuticalsN/A4.554.55BNTCBenitec BiopharmaN/A25.4815.01CRDLCardiol Therapeutics0.012.492.49Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipALLOAllogene Therapeutics83.63%AMLXAmylyx Pharmaceuticals95.84%BNTCBenitec Biopharma52.19%CRDLCardiol Therapeutics12.49%Insider OwnershipCompanyInsider OwnershipALLOAllogene Therapeutics13.20%AMLXAmylyx Pharmaceuticals11.70%BNTCBenitec Biopharma1.30%CRDLCardiol Therapeutics5.25%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableALLOAllogene Therapeutics310218.73 million158.72 millionOptionableAMLXAmylyx Pharmaceuticals20089.14 million60.53 millionOptionableBNTCBenitec Biopharma2025.60 million23.15 millionNo DataCRDLCardiol Therapeutics2082.61 million78.27 millionNot OptionableCRDL, ALLO, AMLX, and BNTC HeadlinesRecent News About These CompaniesCardiol Therapeutics Reports Q1 2025 Financial ResultsMay 27 at 11:53 PM | tipranks.comCardiol Therapeutics to Webcast Virtual Annual General Meeting of Shareholders on May 28th at 4:30 p.m. EDTMay 27 at 7:27 AM | newsfilecorp.com487,295 Shares in Cardiol Therapeutics Inc. (NASDAQ:CRDL) Bought by PVG Asset Management CorpMay 27 at 5:54 AM | marketbeat.comCardiol Therapeutics Reports Q1 2025 Financial ResultsMay 14, 2025 | tipranks.comCardiol Therapeutics Inc. (NASDAQ:CRDL) Given Consensus Rating of "Buy" by AnalystsMay 10, 2025 | marketbeat.comEnvestnet Asset Management Inc. Makes New Investment in Cardiol Therapeutics Inc. (NASDAQ:CRDL)May 8, 2025 | marketbeat.comAdvisorShares Investments LLC Lowers Position in Cardiol Therapeutics Inc. (NASDAQ:CRDL)May 1, 2025 | marketbeat.comCardiol Therapeutics Nominates Dr. Timothy Garnett to Its Board of DirectorsApril 29, 2025 | newsfilecorp.comCardiol Therapeutics Stock: Is Cannabis Potential Priced In?April 22, 2025 | zacks.comCardiol Therapeutics starts phase III trial for heart drugApril 18, 2025 | uk.investing.comRoth MKM Sticks to Its Buy Rating for Cardiol Therapeutics (CRDL)April 18, 2025 | markets.businessinsider.comCardiol Therapeutics Enrolls First Patient in Pivotal Phase III MAVERIC Trial in Recurrent PericarditisApril 16, 2025 | newsfilecorp.comCardiol Therapeutics Reports Increased Losses Amid Rising ExpensesApril 14, 2025 | tipranks.comWe're Keeping An Eye On Cardiol Therapeutics' (TSE:CRDL) Cash Burn RateApril 2, 2025 | finance.yahoo.comCardiol Therapeutics Announces Year-End 2024 Update on OperationsApril 1, 2025 | newsfilecorp.comCardiol Therapeutics to Present at TD Cowen 45th Annual Health Care ConferenceMarch 3, 2025 | newsfilecorp.comCardiol Therapeutics says study shows benefit of cannabidiol drug in treating heart failureFebruary 20, 2025 | proactiveinvestors.comCardiol Therapeutics Announces Publication of Research in the Journal of the American College of Cardiology: Basic to Translational Science That Supports Development of Its Proprietary Subcutaneous Drug Candidate, CRD-38, for the Treatment of Heart FailureFebruary 20, 2025 | newsfilecorp.comCardiol Therapeutics: Bargain Stock Price With Share Price Appreciation CatalystsFebruary 19, 2025 | seekingalpha.comCardiol Therapeutics to Present at Oppenheimer 35th Annual Healthcare Life Sciences ConferenceFebruary 4, 2025 | newsfilecorp.com5 Small Drug Stocks to Add to Your Kitty in the Trump 2.0 EraJanuary 31, 2025 | zacks.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All HeadlinesBullish NVIDIA Market Set to Surge 50% Ahead of Q1 EarningsBy Thomas Hughes | May 27, 2025View Bullish NVIDIA Market Set to Surge 50% Ahead of Q1 EarningsNavitas Soars on NVIDIA Deal: Breaking Down Its Tech and OutlookBy Leo Miller | May 27, 2025View Navitas Soars on NVIDIA Deal: Breaking Down Its Tech and OutlookQualcomm Is 5x Cheaper Than AMD, But Won’t Be for LongBy Sam Quirke | May 13, 2025View Qualcomm Is 5x Cheaper Than AMD, But Won’t Be for LongWhy D-Wave's Project With Davidson Is a Game-Changer For QuantumBy Nathan Reiff | April 30, 2025View Why D-Wave's Project With Davidson Is a Game-Changer For QuantumIs Eli Lilly a Buy After Weak Earnings and CVS-Novo Partnership?By Leo Miller | May 6, 2025View Is Eli Lilly a Buy After Weak Earnings and CVS-Novo Partnership?CRDL, ALLO, AMLX, and BNTC Company DescriptionsAllogene Therapeutics NASDAQ:ALLO$1.14 +0.06 (+5.56%) Closing price 05/28/2025 04:00 PM EasternExtended Trading$1.14 0.00 (-0.44%) As of 06:22 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Allogene Therapeutics, Inc., a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult patients with R/R CD19 positive B-cell acute lymphoblastic leukemia (ALL). The company also develops cemacabtagene ansegedleucel, an engineered allogeneic CAR T cell product candidate that targets CD19 for the treatment of large B-cell lymphoma; and is in Phase 1b clinical trial for the treatment of chronic lymphocytic leukemia. In addition, it is developing ALLO-715, an allogeneic CAR T cell product candidate that is in a Phase 1 clinical trial for treating R/R multiple myeloma; ALLO-605, an allogeneic CAR T cell product candidate that is in a Phase I clinical trial for the treatment of multiple myeloma; ALLO-647, an anti-CD52 monoclonal antibody; CD70 to treat renal cell cancer; ALLO-316, an allogeneic CAR T cell product candidate that is in Phase 1 clinical trial for the treatment of advanced or metastatic RCC; ALLO-329 for the treatment of certain autoimmune diseases; DLL3 for the treatment of small cell lung cancer and other aggressive neuroendocrine tumors; and Claudin 18.2 for the treatment of gastric and pancreatic cancer. The company has license and collaboration agreements with Pfizer Inc.; Servier; Cellectis S.A.; and Notch Therapeutics Inc. It also has a strategic collaboration agreement with The University of Texas MD Anderson Cancer Center for the preclinical and clinical investigation of allogeneic CAR T cell product candidates; and a strategic partnership with Foresight Diagnostics to develop MRD-based In-Vitro Diagnostic for use in ALPHA3. The company was incorporated in 2017 and is headquartered in South San Francisco, California.Amylyx Pharmaceuticals NASDAQ:AMLX$4.79 +0.07 (+1.48%) Closing price 05/28/2025 04:00 PM EasternExtended Trading$4.88 +0.09 (+1.77%) As of 04:54 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Amylyx Pharmaceuticals, Inc., a commercial-stage biotechnology company, engages in the discovery and development of treatment for amyotrophic lateral sclerosis (ALS) and neurodegenerative diseases. The company's products include RELYVRIO, a dual UPR-Bax apoptosis inhibitor composed of sodium phenylbutyrate and taurursodiol for the treatment of ALS in adults in the United States and marketed as ALBRIOZA for the treatment of ALS in Canada. It is also developing AMX0114 for other neurodegenerative diseases. Amylyx Pharmaceuticals, Inc. was founded in 2013 and is headquartered in Cambridge, Massachusetts.Benitec Biopharma NASDAQ:BNTC$16.14 +1.82 (+12.71%) Closing price 05/28/2025 04:00 PM EasternExtended Trading$16.12 -0.02 (-0.09%) As of 05/28/2025 06:07 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Benitec Biopharma Inc., a clinical-stage biotechnology company, focuses on the development of novel genetic medicines. The company develops DNA-directed RNA interference-based therapeutics for chronic and life-threatening human conditions. It is developing BB-301, an adeno-associated virus based gene therapy agent for treating oculopharyngeal muscular dystrophy. The company was incorporated in 1995 and is headquartered in Hayward, California.Cardiol Therapeutics NASDAQ:CRDL$1.28 +0.12 (+10.34%) Closing price 05/28/2025 04:00 PM EasternExtended Trading$1.30 +0.02 (+1.56%) As of 04:00 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Cardiol Therapeutics Inc., a clinical-stage life sciences company, focuses on the research and development of anti-fibrotic and anti-inflammatory therapies for the treatment of heart diseases. Its lead product CardiolRx, which is in Phase II multi-national, randomized, double-blind, and placebo-controlled study to evaluate the efficacy and safety of CardiolRx in acute myocarditis, as well as for the treatment of recurrent pericarditis. The company is also developing CRD-38 injection for subcutaneous administration that is in preclinical development for the treatment of heart failure. It has a license agreement with Meros. The company was incorporated in 2017 and is headquartered in Oakville, Canada. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Toyota Supercharges Joby: $250M Capital Infusion Ignites Stock GameStop Buys Bitcoin: Smart Strategy or Big Mistake? Qualcomm Stock Turns South: 3 Entry Signals to Watch For D-Wave Quantum Stock: Are Advantage2 Gains Here to Stay? Meta's Institutional & Insider Data Fuels Bulls Despite Disparity Is Michael Burry Right Betting Against the Market Again? Amer Sports: The New ONON and DECK of Consumer Discretionary? BigBear.ai: Risky AI Stock or Defense Tech Opportunity? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
